Dagfinn Moseng

TL;DR: HS patients have identified several critical unmet needs that will require stakeholder collaboration to meaningfully address in multidisciplinary care, treatment, research, advocacy, and philanthropy.

TL;DR: Using immunohistochemistry one disease becomes two and a clinical‐pathological review of hidradenitis suppurativa is reviewed, finding that using immunohists to diagnose the disease is more beneficial than chemotherapy.

TL;DR: The Scandinavian Registry for HS, HISREG, is presented, which aims to establish a registry of HS in order to address the following important issues: to assess the safety and effectiveness of different treatments; to identify which specific patient subgroups have the best risk/benefit ratio for a given treatment; and to create benchmark data for quality assurance of the medical service.

TL;DR: There are several factors that appear to positively influence satisfaction with treatment among patients with HS, including treatment by a dermatologist and treatment with a biologic medication, which may support partnered decision making and improve treatment outcomes.

TL;DR: In this paper , the authors found that younger age, Black race, high BMI, active smoking, flares, depression, anxiety, high comorbidity burden, disability, and difficult access to a dermatologist adversely influence life impact related to having hidradenitis suppurativa.